Membrane fatty acid receptors in the β-cell: Novel therapeutic targets for type 2 diabetes;Les récepteurs membranaires des acides gras de la cellule β: De nouvelles cibles thérapeutiques pour le traitement du diabète de type 2?

Medecine/Sciences

Volumn 29, Issue 8-9, 2013, Pages 715-721

  Mancini, Arturo D ^a   Poitout, Vincent ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; FATTY ACID; FFAR1 PROTEIN, HUMAN; FFAR3 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 43, HUMAN; G-PROTEIN COUPLED RECEPTOR 43, HUMAN; GPR119 PROTEIN, HUMAN; O3FAR1 PROTEIN, HUMAN;

ARTICLE; CHEMISTRY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; FATTY ACIDS; HUMANS; INSULIN-SECRETING CELLS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84884609408     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2013298009     Document Type: Article

References (56)

1. Stein DT, Esser V, Stevenson BE, et al. Essentiality of circulating fatty acids for glucosestimulated insulin secretion in the fasted rat. J Clin Invest 1996; 97: 2728-35.
2. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, et al. Fatty acid signaling in the {beta}-cell and insulin secretion. Diabetes 2006; 55: S16-23.
3. Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278: 11303-11.
4. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422: 173-6.
5. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-4.
6. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 2003; 303: 1047-52.
7. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278: 25481-9.
8. Wang J, Wu X, Simonavicius N, et al. Medium-chain fatty acids as ligands for orphan G proteincoupled receptor GPR84. J Biol Chem 2006; 281: 34457-64.
9. Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3: 167-75.
10. Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 2013; doi: 10.1016/j.tem.2013.03. 003.
11. Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009; 58: 1067-76.
12. Vettor R, Granzotto M, De Stefani D, et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab 2008; 93: 3541-50.
13. Poitout V, Amyot J, Semache M, et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801: 289-98.
14. Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metabol 2005; 1: 245-58.
15. Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 2009; 58: 1035-6.
16. Tan CP, Feng Y, Zhou YP, et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008; 57: 2211-9.
17. Tsujihata Y, Ito R, Suzuki M, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 2011; 339: 228-37.
18. Lin DC, Zhang J, Zhuang R, et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 2011; 6: e27270.
19. Luo J, Swaminath G, Brown SP, et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 2012; 7: e46300.
20. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403-11.
21. Kaku K, Araki T, Yoshinaka R. Randomized, double-Blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013; 36: 245-50.
22. Liou AP, Lu X, Sei Y, et al. The G protein-coupled receptor GPR40 directly mediates long chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 2011; 140: 903-12.
23. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008; 57: 2280-7.
24. Flodgren E, Olde B, Meidute-Abaraviciene S, et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007; 354: 240-5.
25. Hirasawa A, Itsubo C, Sadakane K, et al. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem Biophys Res Commun 2008; 365: 22-8.
26. Wang L, Zhao Y, Gui B, et al. Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet (alpha)-cells. J Endocrinol 2011; 210: 173-9.
27. Yashiro H, Tsujihata Y, Takeuchi K, et al. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 2012; 340: 483-9.
28. Tanaka T, Katsuma S, Adachi T, et al. Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 377: 523-7.
29. Oh da Y, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010; 142: 687-98.
30. Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012; 483: 350-4.
31. Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab 2009; 11: 10-20.
32. Taneera J, Lang S, Sharma A, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metabolism 2012; 16: 122-34.
33. Martin C, Passilly-Degrace P, Chevrot M, et al. Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J Lipid Res 2012; 53: 2256-65.
34. Kaji I, Karaki S, Tanaka R, Kuwahara A. Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol 2011; 42: 27-38.
35. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61: 364-71.
36. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-9.
37. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-6.
38. Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005; 146: 5092-9.
39. Zaibi MS, Stocker CJ, O'Dowd J, et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 2010; 584: 2381-6.
40. Ge H, Li X, Weiszmann J, et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008; 149: 4519-26.
41. Ximenes HMA, Hirata AE, Rocha MS, et al. Propionate inhibits glucoseinduced insulin secretion in isolated rat pancreatic islets. Cell Biochem Funct 2007; 25: 173-8.
42. Schmidt J, Smith NJ, Christiansen E, et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem 2011; 286: 10628-40.
43. Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G proteincoupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007; 148: 2601-9.
44. Chu ZL, Carroll C, Chen R, et al. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol 2010; 24: 161-70.
45. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009; 58: 1058-66.
46. Lan H, Vassileva G, Corona A, et al. GPR119 is required for physiological regulation of glucagonlike peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009; 201: 219-30.
47. Alquier T, Peyot ML, Latour MG, et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 2009; 58: 2607-15.
48. Ferdaoussi M, Bergeron V, Zarrouki B, et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012; 55: 2682-92.
49. Watson SJ, Brown AJH, Holliday ND. Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol 2012; 81: 631-42.
50. Ning Y, O'Neill K, Lan H, et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 2008; 155: 1056-65.
51. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012; 52: 1007-16.
52. Lin DC, Guo Q, Luo J, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 2012; 82: 843-59.
53. Ohishi T, Yoshida S. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 2012; 21: 321-8.
54. Lauffer L, Iakoubov R, Brubaker PL. GPR119: Double-dipping for better glycemic control. Endocrinology 2008; 149: 2035-7.
55. Katz LB, Gambale JJ, Rothenberg PL, et al. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 2012; 14: 709-16.
56. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol 2012; 3: 111.